Mesothelioma Second-Line Treatment 2026: 4 Evidence-Based Pathways After First-Line Therapy

When first-line treatment for pleural mesothelioma stops working, the next decision used to be simple — there was almost nothing else to offer. That has changed. As of 2026, four evidence-based second-line pathways have published phase 2 randomized data, and the American Society of Clinical Oncology's 2025 guideline update gives most of them strong recommendations.^[1][2]

Why Did Mesothelioma Treatment Sequencing Become a Question in 2020?

For nearly two decades, the second-line conversation barely existed. Vogelzang's landmark phase 3 trial established pemetrexed plus cisplatin as the first-line standard in 2003, and almost every patient who progressed after chemotherapy ran out of evidence-based options.^[9] Trials of single-agent vinorelbine or gemcitabine in second or third-line gave median progression-free survival of about 1.7 months and partial response rates near 2% — closer to the placebo arms of modern studies than to active therapy.^[6]

The CheckMate 743 phase 3 trial changed the entry point of the disease. Published in The Lancet in January 2021, it showed that nivolumab plus ipilimumab improved median overall survival compared to chemotherapy in unresectable pleural mesothelioma, and the FDA approved the combination in October 2020.^[8] By 2025, ASCO's guideline made dual immunotherapy the default first-line for nearly all patients. That shift created a new clinical question: what do you give next?^[1]

What Are the Four Pathways in the ASCO 2025 Guideline?

ASCO's expert panel split the second-line landscape by what the patient received first.^[1][2] The mapping looks like this:

Key Facts: Mesothelioma Second-Line Treatment 2026

• Gemcitabine plus ramucirumab — strong recommendation after first-line chemotherapy (RAMES, phase 2 RCT, n=161).^[3]
• Oral vinorelbine — strong recommendation after first-line chemotherapy (VIM, phase 2 RCT).^[4]
• Nivolumab with or without ipilimumab — option after first-line chemotherapy (MAPS-2, phase 2).^[5]
• Pemetrexed plus platinum, with or without bevacizumab — recommended after first-line immunotherapy.^[1][7]
• Pemetrexed maintenance after first-line is no longer recommended; gemcitabine switch maintenance may be offered.^[1]
• Pemetrexed rechallenge is reasonable if a patient had a good initial response and a meaningful treatment-free interval.^[1]
• No phase 3 randomized trial has yet established a single second-line standard.^[2]
• PD-L1, tumor mutational burden, and microsatellite instability are not used to guide treatment decisions in pleural mesothelioma.^[1]
• ECOG performance status of 3 or higher: palliative care is recommended instead of additional systemic therapy.^[1]
• Clinical trial enrollment remains a strong option at every line of therapy.^[13]

What Did the RAMES Trial Show for Gemcitabine Plus Ramucirumab?

The RAMES trial enrolled 161 patients with histologically confirmed pleural mesothelioma that had progressed during or after first-line pemetrexed plus platinum, across 26 hospitals in Italy. Patients were randomized 1:1 to gemcitabine 1,000 mg/m² on days 1 and 8 every 21 days plus either intravenous placebo or ramucirumab 10 mg/kg.^[3]

Median overall survival reached 13.8 months in the ramucirumab arm versus 7.5 months in the placebo arm, with a hazard ratio of 0.71 in favor of ramucirumab. Median progression-free survival was 6.4 months versus 3.3 months. The benefit held across age groups, histology, and time to progression on first-line therapy. Grade 3–4 adverse events occurred in 44% of patients receiving ramucirumab versus 30% in the placebo arm — predominantly neutropenia and hypertension — with no treatment-related deaths reported.^[3]

"RAMES is the cleanest second-line evidence we have. A 6.3-month overall survival improvement in pretreated pleural mesothelioma is meaningful — and the toxicity profile is manageable for patients with good performance status." — David Foster, MESO Podcast

What Did the VIM Trial Establish for Oral Vinorelbine?

The VIM trial randomized patients with relapsed pleural mesothelioma 2:1 to oral vinorelbine plus active symptom control versus active symptom control alone, every 3 weeks until disease progression. Eligible patients were age 18 or older, ECOG 0 or 1, with histologically confirmed pleural mesothelioma after platinum-based chemotherapy and radiologic evidence of progression.^[4]

Vinorelbine met the trial's primary progression-free survival endpoint, supporting its activity in relapsed pleural mesothelioma and providing the first randomized phase 2 evidence for an oral chemotherapy option in this setting. Because no FDA-approved drug exists for relapsed mesothelioma, oral vinorelbine in the United States is given off-label — but ASCO's guideline gives it a strong second-line recommendation based on these data.^[1][4]

How Did MAPS-2 Position Immunotherapy Before CheckMate 743?

The MAPS-2 trial (IFCT-1501) was conducted across 21 hospitals in France and remains foundational for understanding immunotherapy in relapsed pleural mesothelioma. Patients with pleural mesothelioma that had progressed after first-line pemetrexed plus platinum were randomized in a non-comparative phase 2 design to nivolumab alone or nivolumab plus ipilimumab. Both arms exceeded the prespecified 12-week disease control rate threshold of 40% by blinded independent central review.^[5]

MAPS-2 was the first major signal that immune checkpoint inhibitors had real activity in pretreated pleural mesothelioma — and it set the stage for CheckMate 743 to test the combination in first-line. Today, MAPS-2 mainly informs the second-line setting for patients who never received immunotherapy upfront, including those treated before 2020.^[5] Patients exploring this pathway should review the broader landscape covered on the WikiMesothelioma Immunotherapy for Mesothelioma page.

What Does the 2025 Japanese Study Tell Us About Pemetrexed-Platinum After Immunotherapy?

The new sequencing question — what to give after first-line nivolumab plus ipilimumab — does not yet have a randomized trial answer. The closest data come from a 2025 multicenter Japanese retrospective observational study of 43 patients with unresectable, advanced, or metastatic pleural mesothelioma who received pemetrexed plus a platinum agent after first-line nivolumab-ipilimumab.^[7]

Median overall survival was 17.1 months (95% CI: 9.3 to not estimable). Median progression-free survival was 5.7 months (95% CI: 3.9–11.9). One-year overall survival was 62.8% and one-year progression-free survival was 26.2%. Among patients with measurable lesions, the objective response rate was 30.3% and the disease control rate was 69.7%. The authors concluded that these results "are similar to those of previous studies on pemetrexed-platinum for pleural mesothelioma in first-line settings," supporting pemetrexed-platinum as an appropriate second-line choice after immunotherapy.^[7]

"Forty-three patients is a modest sample, but the signal is consistent: pemetrexed-platinum keeps working after immunotherapy. That matters because most newly diagnosed patients today will get nivo-ipi first — and they need to know what comes next." — David Foster, MESO Podcast

How Should Histology and Performance Status Shape the Decision?

Histology drives the first-line choice, and that choice cascades into second-line. Non-epithelioid mesothelioma (sarcomatoid or biphasic) responds poorly to chemotherapy and is preferentially treated with first-line nivolumab plus ipilimumab in the ASCO 2025 guideline.^[1] Those patients move to pemetrexed-platinum at progression. Epithelioid mesothelioma still has multiple acceptable first-line options — pemetrexed-platinum with or without bevacizumab, nivolumab plus ipilimumab, or pembrolizumab plus chemotherapy (IND.227 / KEYNOTE-483) — so the second-line conversation is more individualized.^[11]

Performance status sets the ceiling. ECOG 0–1 patients have access to all four second-line pathways and clinical trials. ECOG 2 patients can be offered single-agent chemotherapy with careful supportive care. Patients with ECOG 3 or higher should be referred to palliative care rather than further systemic therapy — a recommendation now backed by guideline-level evidence.^[1] For a deeper discussion of how prognostic factors shape these decisions, see our review of ECOG performance status and other mesothelioma prognostic factors.

Where Do Tumor Treating Fields and Pembrolizumab-Chemo Fit?

Tumor Treating Fields (TTFields) at 150 kHz combined with pemetrexed and platinum chemotherapy was tested in the STELLAR trial — an 80-patient single-arm phase 2 study reporting 18.2-month median overall survival in unresectable pleural mesothelioma.^[10] The FDA approved this combination as a first-line option, not a second-line one. There are no published randomized data placing TTFields specifically in the second-line setting.

Pembrolizumab plus pemetrexed and platinum chemotherapy (the IND.227 regimen, FDA-approved in 2024 based partly on the data published in JCO in 2023) is also a first-line option, not a second-line one. Patients who progress on this regimen are not specifically addressed in the ASCO 2025 guideline as a separate sequencing pathway — they are typically managed using the same second-line framework as patients who received first-line chemotherapy.^[11] For a fuller summary of available immunotherapy options including ASCO's first-line immunotherapy recommendations, see our companion article.

Why Do Clinical Trials Remain Important at Second-Line?

Every published second-line trial in pleural mesothelioma is phase 2. There is no phase 3 randomized evidence establishing a single global standard. The data gaps named in ASCO's 2025 guideline include the optimal sequence after first-line chemoimmunotherapy, immunotherapy rechallenge after a durable initial response, and any biomarker-driven selection.^[1][2]

ClinicalTrials.gov currently lists active studies of mesothelin-targeted CAR T-cell therapy, dendritic cell vaccines, ADI-PEG 20 (the ATOMIC-Meso program for ASS1-deficient tumors), and bispecific antibody platforms, several of which enroll patients after second or third-line systemic therapy.^[13] The Mesothelioma Clinical Trials WikiMesothelioma reference page tracks the most active trials by sponsor and target. Patients who have exhausted the four guideline pathways should ask their treatment center about trial eligibility before assuming nothing else exists.

"I tell every patient: clinical trials are not 'last resort medicine.' Some of the most promising data right now is in trials, not in approved labels. If your specialist has not raised a trial discussion by second-line, that is a conversation to start." — David Foster, MESO Podcast

Why Should Palliative Care Start at Diagnosis, Not at the End?

Earlier integration of palliative care has consistently improved quality of life, mood, and symptom control in advanced thoracic cancers, and ASCO now recommends early palliative care for all mesothelioma patients regardless of treatment line.^[1] In real-world cohorts, the median time from palliative care referral to death has historically been only a few months — far too late for patients to benefit from symptom management, advance care planning, or family support. The fix is a referral at or near diagnosis, not after second or third-line systemic therapy has failed.^[12] This applies whether a patient is heading into a clinical trial, a fourth-line attempt, or best supportive care alone — palliative care is additive, not a substitute.

What Does This Mean for Mesothelioma Patients in 2026?

Treatment for relapsed pleural mesothelioma has more evidence behind it now than at any prior point in the disease's history. Four pathways have phase 2 randomized data. ASCO's 2025 guideline gives most of them strong recommendations. Sequencing depends on what came first, what the patient tolerated, and what their histology and performance status allow.^[1]

What second-line treatment cannot do — yet — is replicate the kind of long-term durable response that nivolumab plus ipilimumab produces in a subset of first-line patients. That is the biggest open question for the next decade. Until it is answered by phase 3 trials, the right approach is to match the patient to the best evidence-based option, integrate palliative care early, and consider clinical trials at every step. Patients exploring their legal options alongside treatment can review the firm's mesothelioma legal resources at Dandell.com or our overview at Mesothelioma Lawyer Center.

References

1. Kindler HL, Ismaila N, Bazhenova L, et al. Treatment of Pleural Mesothelioma: ASCO Guideline Update. Journal of Clinical Oncology. 2025;43(8):1006-1038.
2. Kindler HL, Dagogo-Jack I, de Perrot M, Drazer MW, et al. Treatment of Pleural Mesothelioma: ASCO Guideline Clinical Insights. JCO Oncology Practice. 2025.
3. Pinto C, Zucali PA, Pagano M, et al. Gemcitabine with or without ramucirumab as second-line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Oncology. 2021;22(10):1438-1447.
4. Fennell DA, Casbard A, Porter C, et al. Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial. EClinicalMedicine. 2022;48:101432.
5. Scherpereel A, Mazieres J, Greillier L, et al. Nivolumab or nivolumab plus ipilimumab in patients with relapsed malignant pleural mesothelioma (IFCT-1501 MAPS2): a multicentre, open-label, randomised, non-comparative, phase 2 trial. The Lancet Oncology. 2019;20(2):239-253.
6. Zauderer MG, Kass SL, Woo K, Sima CS, et al. Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma. Lung Cancer. 2014.
7. Ono S, Taniguchi H, Kuroda K, et al. Pemetrexed plus platinum as second-line treatment for patients with pleural mesothelioma treated with nivolumab plus ipilimumab. Lung Cancer. 2025;207:108709.
8. Baas P, Scherpereel A, Nowak AK, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. The Lancet. 2021;397(10272):375-386.
9. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. Journal of Clinical Oncology. 2003;21(14):2636-2644.
10. Ceresoli GL, Aerts JG, Dziadziuszko R, et al. Tumour Treating Fields in combination with pemetrexed and cisplatin or carboplatin as first-line treatment for unresectable malignant pleural mesothelioma (STELLAR): a multicentre, single-arm phase 2 trial. The Lancet Oncology. 2019;20(12):1702-1709.
11. Chu Q, Perrone F, Greillier L, et al. Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial. The Lancet. 2023;402(10419):2295-2306.
12. Malignant Mesothelioma Treatment (PDQ®) – Health Professional Version. National Cancer Institute.
13. Active Mesothelioma Clinical Trials. ClinicalTrials.gov, U.S. National Library of Medicine.
14. Chemotherapy for Mesothelioma. WikiMesothelioma.
15. Immunotherapy for Mesothelioma. WikiMesothelioma.